These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1029 related articles for article (PubMed ID: 30213523)

  • 1. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.
    Tan TZ; Rouanne M; Tan KT; Huang RY; Thiery JP
    Eur Urol; 2019 Mar; 75(3):423-432. PubMed ID: 30213523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
    Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
    Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A potential prognostic lncRNA signature for predicting survival in patients with bladder urothelial carcinoma.
    Bao Z; Zhang W; Dong D
    Oncotarget; 2017 Feb; 8(6):10485-10497. PubMed ID: 28060759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.
    Seiler R; Ashab HAD; Erho N; van Rhijn BWG; Winters B; Douglas J; Van Kessel KE; Fransen van de Putte EE; Sommerlad M; Wang NQ; Choeurng V; Gibb EA; Palmer-Aronsten B; Lam LL; Buerki C; Davicioni E; Sjödahl G; Kardos J; Hoadley KA; Lerner SP; McConkey DJ; Choi W; Kim WY; Kiss B; Thalmann GN; Todenhöfer T; Crabb SJ; North S; Zwarthoff EC; Boormans JL; Wright J; Dall'Era M; van der Heijden MS; Black PC
    Eur Urol; 2017 Oct; 72(4):544-554. PubMed ID: 28390739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The evolution of bladder cancer genomics: What have we learned and how can we use it?
    Audenet F; Attalla K; Sfakianos JP
    Urol Oncol; 2018 Jul; 36(7):313-320. PubMed ID: 29573965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bladder Tumor Subtype Commitment Occurs in Carcinoma
    Wullweber A; Strick R; Lange F; Sikic D; Taubert H; Wach S; Wullich B; Bertz S; Weyerer V; Stoehr R; Breyer J; Burger M; Hartmann A; Strissel PL; Eckstein M
    Cancer Res; 2021 Mar; 81(6):1552-1566. PubMed ID: 33472889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer.
    Garczyk S; Bischoff F; Schneider U; Golz R; von Rundstedt FC; Knüchel R; Degener S
    Virchows Arch; 2021 Aug; 479(2):325-335. PubMed ID: 33650041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Greater utility of molecular subtype rather than epithelial-to-mesenchymal transition (EMT) markers for prognosis in high-risk non-muscle-invasive (HGT1) bladder cancer.
    Ottley EC; Pell R; Brazier B; Hollidge J; Kartsonaki C; Browning L; O'Neill E; Kiltie AE
    J Pathol Clin Res; 2020 Oct; 6(4):238-251. PubMed ID: 32374509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma.
    Moss TJ; Qi Y; Xi L; Peng B; Kim TB; Ezzedine NE; Mosqueda ME; Guo CC; Czerniak BA; Ittmann M; Wheeler DA; Lerner SP; Matin SF
    Eur Urol; 2017 Oct; 72(4):641-649. PubMed ID: 28601352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Power of a Tumor Differentiation Gene Signature for Bladder Urothelial Carcinomas.
    Mo Q; Nikolos F; Chen F; Tramel Z; Lee YC; Hayashi K; Xiao J; Shen J; Chan KS
    J Natl Cancer Inst; 2018 May; 110(5):448-459. PubMed ID: 29342309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unraveling UCA1 lncRNA prognostic utility in urothelial bladder cancer.
    Avgeris M; Tsilimantou A; Levis PK; Rampias T; Papadimitriou MA; Panoutsopoulou K; Stravodimos K; Scorilas A
    Carcinogenesis; 2019 Aug; 40(8):965-974. PubMed ID: 30815670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer.
    Ochoa AE; Choi W; Su X; Siefker-Radtke A; Czerniak B; Dinney C; McConkey DJ
    Oncotarget; 2016 Dec; 7(49):80164-80174. PubMed ID: 27845906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic screening of protein-coding gene expression identified HMMR as a potential independent indicator of unfavorable survival in patients with papillary muscle-invasive bladder cancer.
    Yang D; Ma Y; Zhao P; Ma J; He C
    Biomed Pharmacother; 2019 Dec; 120():109433. PubMed ID: 31568988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis.
    de Jong JJ; Liu Y; Robertson AG; Seiler R; Groeneveld CS; van der Heijden MS; Wright JL; Douglas J; Dall'Era M; Crabb SJ; van Rhijn BWG; van Kessel KEM; Davicioni E; Castro MAA; Lotan Y; Zwarthoff EC; Black PC; Boormans JL; Gibb EA
    Genome Med; 2019 Oct; 11(1):60. PubMed ID: 31619281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer.
    Komura K; Hirosuna K; Tokushige S; Tsujino T; Nishimura K; Ishida M; Hayashi T; Ura A; Ohno T; Yamazaki S; Nakamori K; Kinoshita S; Maenosono R; Ajiro M; Yoshikawa Y; Takai T; Tsutsumi T; Taniguchi K; Tanaka T; Takahara K; Konuma T; Inamoto T; Hirose Y; Ono F; Shiraishi Y; Yoshimi A; Azuma H
    Mol Cancer; 2023 Nov; 22(1):185. PubMed ID: 37980528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer.
    Genitsch V; Kollár A; Vandekerkhove G; Blarer J; Furrer M; Annala M; Herberts C; Pycha A; de Jong JJ; Liu Y; Krentel F; Davicioni E; Gibb EA; Kruithof-de Julio M; Wyatt AW; Seiler R
    Urol Oncol; 2019 Nov; 37(11):826-836. PubMed ID: 31585777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and molecular characteristics of bladder urothelial carcinoma subtypes.
    Li Y; Yang K; Li K; Liu H; Zhao S; Jiao M; Fu X
    J Cell Biochem; 2019 Jun; 120(6):9956-9963. PubMed ID: 30548659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study.
    Dyrskjøt L; Reinert T; Algaba F; Christensen E; Nieboer D; Hermann GG; Mogensen K; Beukers W; Marquez M; Segersten U; Høyer S; Ulhøi BP; Hartmann A; Stöhr R; Wach S; Nawroth R; Schwamborn K; Tulic C; Simic T; Junker K; Harving N; Petersen AC; Jensen JB; Keck B; Grimm MO; Horstmann M; Maurer T; Steyerberg EW; Zwarthoff EC; Real FX; Malats N; Malmström PU; Ørntoft TF
    Eur Urol; 2017 Sep; 72(3):461-469. PubMed ID: 28583312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular subtypes of urothelial carcinoma are defined by specific gene regulatory systems.
    Eriksson P; Aine M; Veerla S; Liedberg F; Sjödahl G; Höglund M
    BMC Med Genomics; 2015 May; 8():25. PubMed ID: 26008846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extracellular matrix-related genes play an important role in the progression of NMIBC to MIBC: a bioinformatics analysis study.
    Zhang H; Shan G; Song J; Tian Y; An LY; Ban Y; Luo GH
    Biosci Rep; 2020 May; 40(5):. PubMed ID: 32391563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.